William Blair reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report released on Thursday, AnalystRatings.com reports.
A number of other brokerages have also weighed in on AUTL. Zacks Investment Research upgraded Autolus Therapeutics from a sell rating to a hold rating in a research note on Thursday, July 11th. Needham & Company LLC initiated coverage on Autolus Therapeutics in a research note on Monday, September 23rd. They issued a buy rating and a $26.00 target price for the company. HC Wainwright restated a buy rating and issued a $24.00 target price on shares of Autolus Therapeutics in a research note on Thursday, September 12th. Finally, ValuEngine upgraded Autolus Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $33.33.
Shares of AUTL traded down $0.34 during mid-day trading on Thursday, hitting $12.05. The company’s stock had a trading volume of 35,700 shares, compared to its average volume of 155,734. Autolus Therapeutics has a one year low of $9.50 and a one year high of $53.24. The firm has a market capitalization of $573.69 million, a PE ratio of -8.49 and a beta of 0.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 13.12 and a current ratio of 13.12. The stock’s 50-day moving average is $12.51 and its two-hundred day moving average is $15.66.
A number of hedge funds have recently made changes to their positions in the stock. Exane Derivatives acquired a new stake in Autolus Therapeutics in the second quarter worth about $50,000. Virtus ETF Advisers LLC increased its position in Autolus Therapeutics by 105.3% in the second quarter. Virtus ETF Advisers LLC now owns 17,311 shares of the company’s stock worth $279,000 after purchasing an additional 8,877 shares during the period. CWM LLC increased its position in Autolus Therapeutics by 29.3% in the second quarter. CWM LLC now owns 45,384 shares of the company’s stock worth $731,000 after purchasing an additional 10,274 shares during the period. Walleye Trading Advisors LLC acquired a new stake in Autolus Therapeutics in the second quarter worth about $168,000. Finally, Walleye Trading LLC acquired a new stake in Autolus Therapeutics in the second quarter worth about $170,000. Hedge funds and other institutional investors own 51.53% of the company’s stock.
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
See Also: Forex
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.